Healthcare is becoming a central pillar of Japan's long term growth strategy.

Japan's latest Growth Strategy signals a shift in how the government views the life sciences sector, positioning innovation in drug discovery, advanced medicine, synthetic biology, and biotechnology as key drivers of economic growth and industrial competitiveness.

GR Japan examines what these policy developments mean for healthcare companies and highlights the regulatory, pricing, and investment trends to watch over the next 12 to 18 months.

For full findings, please read the attached PDF report.